Illumina

ILMN

Market cap $20.1B

Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition.

SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

What if the biggest winners in biotech weren't the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible?

David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.